BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-argenx-alkivia-myositis-q3-2026@catalyst-calendar.local
DTSTAMP:20260720T200617Z
DTSTART:20260701T130000Z
DTEND:20260701T133000Z
SUMMARY:argenx efgartigimod ALKIVIA肌炎三期顶线数据读出窗口
DESCRIPTION:argenx官方披露efgartigimod治疗肌炎的Phase 3 ALKIVIA顶线结果预计在2026年第三季度公布，或影响FcRn平台在风湿免疫适应症扩展的估值。\\nImpact score: 75\\nExpected: 顶线数据将验证Vyvgart/FcRn机制能否扩展到肌炎并支撑免疫管线长期增长。\\nAffected: ARGX(subject\, unknown\, score 82)\; 09688.HK(licensee\, unknown\, score 70)\; ZLAB(licensee\, unknown\, score 70)\; JNJ(peer\, mixed\, score 52)\; IBB(etf\, mixed\, score 52)\\nSources: argenx Q1 2026 update: https://www.us.argenx.com/news/2026/press-release-3289577\\nZai Lab argenx update: https://ir.zailaboratory.com/news-releases/news-release-details/argenx-presents-new-efgartigimod-data-showing-long-term\\nClinicalTrials.gov ALKIVIA: https://clinicaltrials.gov/study/NCT05523167\\nargenx June 2026 data update: https://www.us.argenx.com/news/2026/press-release-3305765\\nargenx strategic priorities: https://www.us.argenx.com/news/2026/press-release-3216531\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-argenx-alkivia-myositis-q3-2026
CATEGORIES:guidance\,US\,clinical readout\,Phase 3\,FcRn\,myositis\,autoimmune\,efgartigimod\,ALKIVIA
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: argenx efgartigimod ALKIVIA肌炎三期顶线数据读出窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: argenx efgartigimod ALKIVIA肌炎三期顶线数据读出窗口
END:VALARM
END:VEVENT
END:VCALENDAR